Lysozyme gene treatment in testosterone induced benign prostate hyperplasia rat model and comparasion of its' effectiveness with botulinum toxin injection

• Published in: International Brazilian Journal of Urology Vol. 43; no. 6; pp. 1167 - 1175
• Main Authors: Ergün, Osman, Koşar, Pinar Aslan, Onaran, İbrahim, Darici, Hakan, Koşar, Alim
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Urologia 01.11.2017
• Subjects: Animals; Botulinum Toxins; Botulinum Toxins, Type A - therapeutic use; Disease Models, Animal; Genetic Therapy - methods; Male; Muramidase - genetics; Original; Prostatic Hyperplasia; Prostatic Hyperplasia - chemically induced; Prostatic Hyperplasia - drug therapy; Rats; Rats, Wistar; Testosterone; Botulinum Toxins; Prostatic Hyperplasia; Testosterone
• ISSN: 1677-5538; 1677-6119; 1677-6119
• DOI: 10.1590/S1677-5538.IBJU.2016.0677

To compare the effects and histopathological changes of botulinum neurotoxin type A and lysozyme gene injections into prostate tissue within a testosterone induced benign prostate hyperplasia rat model. 40 male Wistar rats were randomized into four Groups. Group-1: Control, Group-2: Testosterone replacement, Group-3: Testosterone+botulinum neurotoxin type A, Group-4: Testosterone+plazmid DNA/liposome complex. Estimated prostate volume of the testosterone injected Groups were higher than the control (p <0.05). Actual prostate weight of the testosterone injected Groups was higher than the control Group (p <0.05). Testosterone undecanoate increased the prostate weight by 39%. Botulinum neurotoxin type A treatment led to an estimated prostate volume and actual prostate weights decreased up to 32.5% in rats leading to prostate apoptosis. Lysozyme gene treatment led to an estimated prostate volume and actual prostate weights decrease up to 38.7%. Lysozyme gene and botulinum neurotoxin type A treatments for prostate volume decreasing effect have been verified in the present study that could be anew modality of treatment in prostatic benign hyperplasia that needs to be verified in large randomized human experimental studies.